From the Journals

Bariatric surgery may cut cancer in obesity with liver disease


 

Does bariatric surgery curb cancer risk in liver disease?

The researchers examined insurance claims data from the national MarketScan database from Jan. 1, 2007, to Dec. 31, 2017, for patients aged 18-64 years who had health insurance from 350 employers and 100 insurers. They identified 98,090 patients with severe obesity who were newly diagnosed with NAFLD during 2008-2017.

Roughly a third of the cohort (33,435 patients) underwent bariatric surgery. From 2008 to 2017, laparoscopic sleeve gastrectomies increased from 4% of bariatric procedures to 68% of all surgeries. Laparoscopic adjustable gastric band and laparoscopic Roux-en-Y gastric bypass procedures fell from 35% to less than 1% and from 49% to 28%, respectively.

Patients who underwent bariatric surgery were younger (mean age, 44 vs. 46 years), were more likely to be women (74% vs. 62%), and were less likely to have a history of smoking (6% vs. 10%).

During a mean follow-up of 22 months (and a median follow-up of 10 months), there were 911 incident cases of obesity-related cancers. These included cancer of the colon (116 cases), rectum (15), breast (in postmenopausal women; 131), kidney (120), esophagus (16), gastric cardia (8), gallbladder (4), pancreas (44), ovaries (74), endometrium (135), and thyroid (143), as well as hepatocellular carcinoma (49), multiple myeloma (50), and meningioma (6). There were 1,912 incident cases of other cancers, such as brain and lung cancers and leukemia.

A total of 258 patients who underwent bariatric surgery developed an obesity-related cancer (an incidence of 3.83 per 1,000 person-years), compared with 653 patients who did not have bariatric surgery (an incidence of 5.63 per 1,000 person-years).

The researchers noted that study limitations include the fact that it was restricted to privately insured individuals aged 18-64 years with severe obesity. In addition, “the short median follow-up may underestimate the full effect of bariatric surgery on cancer risk,” they wrote.

The authors disclosed no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Obesity boosts risks in COVID-19 from diagnosis to death
MDedge Hematology and Oncology
Smart health devices – promises and pitfalls
MDedge Hematology and Oncology
Patient health suffers amid pandemic health care shortages
MDedge Hematology and Oncology
Obesity ‘clearly’ not tied to worse survival in metastatic breast cancer
MDedge Hematology and Oncology
Study flags cardiovascular disease in men with breast cancer
MDedge Hematology and Oncology
BMI, age, and sex affect COVID-19 vaccine antibody response
MDedge Hematology and Oncology
Call to action on obesity amid COVID-19 pandemic
MDedge Hematology and Oncology
CDC data strengthen link between obesity and severe COVID
MDedge Hematology and Oncology
High obesity rates in Southern states magnify COVID threats
MDedge Hematology and Oncology
In U.S., lockdowns added 2 pounds per month
MDedge Hematology and Oncology